▼Naltrexone/bupropion for obesity
Drug and Therapeutics Bulletin · 2017-11 · 55 (11) · 126-129
DOI: 10.1136/dtb.2017.11.0550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug and Therapeutics Bulletin, online erschienen am 08.11.2017. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
▼ Naltrexone/bupropion (Mysimba - Orexigen Therapeutics Ireland Limited) is a fixed-dose combination product for the treatment of adults who are obese or overweight with at least one weight-related comorbidity, as an adjunct to diet and lifestyle modifications. Originally licensed by the European Medicines Agency (EMA) in 2015, it has recently been launched in the UK. Here, we review the evidence for its efficacy and safety and consider its place in therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
(2017). ▼Naltrexone/bupropion for obesity. Drug and Therapeutics Bulletin, 55(11), 126-129. https://doi.org/10.1136/dtb.2017.11.0550
Vancouver
▼Naltrexone/bupropion for obesity. Drug and Therapeutics Bulletin. 2017;55(11):126-129. doi:10.1136/dtb.2017.11.0550
BibTeX
@article{euvimed2017,
title = {▼Naltrexone/bupropion for obesity},
journal = {Drug and Therapeutics Bulletin},
year = {2017},
volume = {55},
number = {11},
pages = {126--129},
doi = {10.1136/dtb.2017.11.0550}
}
EUVIMED